^
    Back
    Association details:
    Biomarker:POLE mutation + POLD1 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Thorac Cancer
    Title:

    Integrating POLE/POLD1 mutated for immunotherapy treatment planning of advanced stage non-small cell lung cancer

    Published date:
    06/22/2023
    Excerpt:
    The cohort with either TMB > 18 or POLE/POLD1 mutated (n = 54, 15.4%) had significant OS improvement with ICI treatment when compared with those without the biomarker signature of POLE/POLD1 mutated or TMB > 18 (p < 0.0001) (Figure 4a).
    DOI:
    https://doi.org/10.1111/1759-7714.15012